福瑞達(600223.SH):公司醫藥業務涵蓋中藥及化藥製劑、生化藥品及銷售團隊
格隆匯8月7日丨福瑞達(600223.SH)近期在接待機構投資者調研時表示,公司醫藥業務涵蓋中藥及化藥製劑、生化藥品及銷售團隊,旗下明仁福瑞達致力於中成藥、化學藥、保健食品的研發、生產和銷售,參股的博士倫福瑞達致力於生物技術產品和生化藥品的研究開發、生產和銷售,另外,在渠道方面觸達大型醫院、縣域醫院及診所,醫藥連鎖、線上藥店等渠道。
未來,醫藥板塊將以臨牀價值與市場需求為導向,聚焦骨、皮膚和眼健康等領域,採用自主開發+合作開發+授權引進的模式,擴充產品管線,持續推動研發、生產、銷售產業鏈融合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.